Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML
对于患有 FLT3 突变型 AML 的老年/体弱患者，可采用去甲基化药物、维奈托克联合 FLT3 抑制剂的“三联疗法”。
期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/s41408-022-00670-0
Yilmaz, Musa; Kantarjian, Hagop; Short, Nicholas J; Reville, Patrick; Konopleva, Marina; Kadia, Tapan; DiNardo, Courtney; Borthakur, Gautam; Pemmaraju, Naveen; Maiti, Abhishek; Jabbour, Elias; Jain, Nitin; Issa, Ghayas; Takahashi, Koichi; Sasaki, Koji; Ohanian, Maro; Pierce, Sherry; Tang, Guillin; Loghavi, Sanam; Patel, Keyur; Wang, Sa A; Garcia-Manero, Guillermo; Andreeff, Michael; Ravandi, Farhad; Daver, Naval
